- HPLC tested for identity and purity; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
Orforglipron (Oral GLP-1 Research Compound)
Non-peptide oral GLP-1 receptor agonist supplied in 30-capsule research bottles
- FormOral capsules in a sealed bottle with desiccant
- Research areasIncretin receptor pharmacology, glucose-dependent insulin secretion, gastric emptying, food-intake and body-composition models
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
Orforglipron is a small-molecule, non-peptide agonist of the glucagon-like peptide-1 receptor. That single sentence explains why it draws so much research attention: every widely studied incretin agent before it — semaglutide, liraglutide, tirzepatide — is a peptide, which constrains oral delivery because peptides are digested and absorbed poorly. Orforglipron instead occupies the receptor as a conventional drug-like molecule, so it is studied as an orally administered compound without absorption enhancers such as SNAC.
Specifications
Supply & purity
- Form
- Oral capsules in a sealed bottle with desiccant
- Purity
- HPLC tested for identity and purity; lot-matched COA available
- Available sizes
- 3 mg × 30 capsules, 12 mg × 30 capsules
Additional detail
- Compound class
- Non-peptide small-molecule GLP-1 receptor agonist
- Molecular target
- Glucagon-like peptide-1 receptor (GLP-1R), a class B GPCR
- Signalling profile
- Biased partial agonism — cAMP/Gs-favoured with reduced β-arrestin recruitment
- Structural note
- Small organic molecule; no amino acid sequence and no peptide backbone
- Also known as
- LY3502970, OWL833
- Delivery note
- Studied as an oral compound without SNAC or other peptide absorption enhancers
- Research areas
- Incretin receptor pharmacology, glucose-dependent insulin secretion, gastric emptying, food-intake and body-composition models
- Regulatory status
- Investigational compound; not supplied as an approved medicine
- Reconstitution
- None required — supplied in finished capsule form
- Storage
- Room temperature in the sealed bottle, protected from light, heat and humidity
Questions about Orforglipron (Oral GLP-1 Research Compound)
What is orforglipron?
Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor. It is studied as an orally administered incretin agonist and is used in research as the small-molecule comparator against peptide GLP-1 analogues such as semaglutide and tirzepatide.
How does it differ from oral semaglutide?
Oral semaglutide is a peptide formulated with the absorption enhancer SNAC to survive the gut. Orforglipron is not a peptide at all, so it is investigated as a conventional oral small molecule. The two also differ in receptor signalling profile, orforglipron being described as a biased partial agonist.
How is purity verified?
Each lot is tested by HPLC for identity and purity, and a lot-matched Certificate of Analysis is available on this page before you order. The COA documents the analytical methods used and the results obtained for the specific lot supplied.
What sizes are available?
Orforglipron is supplied in 3 mg × 30 capsule and 12 mg × 30 capsule bottles. The two strengths let laboratories build concentration comparisons without re-weighing bulk powder, and both ship in sealed bottles with desiccant.
How should it be stored?
Store the sealed bottle at room temperature, protected from light, heat and humidity, with the desiccant left in place. Avoid transferring capsules to unlabelled containers, and record the lot number and opening date so material stays traceable.
Related
